Camurus AB (publ) (CAMRF)
USD 50.97
(0.0%)
USD 50.97
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 24.5 Million SEK | -6.52% |
| 2022 | 26.21 Million SEK | 2.19% |
| 2021 | 25.65 Million SEK | 0.69% |
| 2020 | 25.48 Million SEK | -6.77% |
| 2019 | 27.33 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 22.81 Million SEK | -6.91% |
| 2024 Q2 | 20.95 Million SEK | -8.15% |
| 2023 Q4 | 24.5 Million SEK | -3.1% |
| 2023 FY | 24.5 Million SEK | -6.52% |
| 2023 Q1 | 24 Million SEK | -8.44% |
| 2023 Q2 | 26.77 Million SEK | 11.54% |
| 2023 Q3 | 25.29 Million SEK | -5.54% |
| 2022 Q1 | 23.98 Million SEK | -6.5% |
| 2022 FY | 26.21 Million SEK | 2.19% |
| 2022 Q3 | 25.13 Million SEK | 12.7% |
| 2022 Q4 | 26.21 Million SEK | 4.32% |
| 2022 Q2 | 22.3 Million SEK | -7.04% |
| 2021 Q4 | 25.65 Million SEK | -2.99% |
| 2021 Q3 | 26.44 Million SEK | 15.31% |
| 2021 FY | 25.65 Million SEK | 0.69% |
| 2021 Q1 | 24.21 Million SEK | -4.96% |
| 2021 Q2 | 22.93 Million SEK | -5.28% |
| 2020 Q3 | 23.74 Million SEK | -5.57% |
| 2020 FY | 25.48 Million SEK | -6.77% |
| 2020 Q2 | 25.14 Million SEK | -4.22% |
| 2020 Q1 | 26.25 Million SEK | -3.94% |
| 2020 Q4 | 25.48 Million SEK | 7.3% |
| 2019 Q3 | 26.21 Million SEK | -3.04% |
| 2019 FY | 27.33 Million SEK | 0.0% |
| 2019 Q4 | 27.33 Million SEK | 4.27% |
| 2019 Q2 | 27.03 Million SEK | -2.95% |
| 2019 Q1 | 27.85 Million SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1594.439% |
| CSL Limited | 12.18 Billion USD | 99.799% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 40.521% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -494.548% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -5998.559% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 43.497% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 17.671% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -2484.388% |
| Mesoblast Limited | 118.7 Million USD | 79.354% |
| Marizyme, Inc. | 18.71 Million USD | -30.931% |
| Genus plc | 233.1 Million USD | 89.486% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -736.306% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1724.002% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -3167.6% |
| ContraFect Corporation | 2.88 Million USD | -750.642% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -17988.082% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 28.88 Million USD | 15.153% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -333.112% |
| MultiCell Technologies, Inc. | 202.58 USD | -12097342.985% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 57.371% |
| EV Biologics, Inc. | 1.49 Million USD | -1539.537% |
| Q BioMed Inc. | 4.1 Million USD | -496.28% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 25.963% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1895.098% |
| Biomind Labs Inc. | 735.54 Thousand USD | -3231.829% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -88.559% |
| Skye Bioscience, Inc. | 4.61 Million USD | -430.999% |
| SQZ Biotechnologies Company | 27.47 Million USD | 10.79% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -17217.232% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -317.418% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -953.632% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -95187.531% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -3789.525% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 85.714% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -2659.598% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -985.158% |
| GB Sciences, Inc. | 1.75 Million USD | -1292.992% |
| Alpha Cognition Inc. | 1.22 Million USD | -1908.158% |
| argenx SE | 20 Million USD | -22.535% |
| HST Global, Inc. | 98.31 Thousand USD | -24826.006% |
| Halberd Corporation | 150 Thousand USD | -16238.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -2359.707% |
| Resverlogix Corp. | 6.49 Million USD | -277.554% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -9488.328% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 46.209% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 63.77% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -709.83% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -246.496% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -6712.988% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -804.75% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| ONE Bio Corp. | 19.71 Million USD | -24.306% |
| Zenith Capital Corp. | 10.22 Thousand USD | -239577.262% |
| Genscript Biotech Corporation | 417.73 Million USD | 94.133% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -12115.875% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -922.094% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -10588.165% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -16385.934% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -9753.249% |
| Agentix Corp. | 50 Thousand USD | -48914.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 891.22 Thousand USD | -2649.808% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -20.558% |
| BioStem Technologies, Inc. | 4.71 Million USD | -420.162% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -9695.669% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -72824.478% |
| Cell Source, Inc. | 9.25 Million USD | -164.821% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -3140.792% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -3140.792% |
| NovAccess Global Inc. | 2.19 Million USD | -1014.015% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -10630.941% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -11516.068% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -391.812% |
| CytoDyn Inc. | 30.07 Million USD | 18.516% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -6865.243% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -213.39% |
| SYBLEU INC | 477.5 Thousand USD | -5032.356% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -19905.714% |
| Rebus Holdings, Inc. | 310 Thousand USD | -7805.484% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -417.54% |
| Mobile Lads Corp. | 484.28 Thousand USD | -4960.46% |
| International Stem Cell Corporation | 4.17 Million USD | -486.573% |
| Bioxytran, Inc. | 1.92 Million USD | -1173.091% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -39165.858% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1023.71% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -194.697% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -185.463% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1475.528% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -9044.403% |
| Neutra Corp. | 54.15 Thousand USD | -45152.604% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -1239.18% |
| PureTech Health plc | 25.51 Million USD | 3.939% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1901.836% |
| IXICO plc | 472.02 Thousand USD | -5091.908% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -58.099% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 60.64% |
| CSL Limited | 12.18 Billion USD | 99.799% |
| Cellectis S.A. | 92.77 Million USD | 73.585% |